University of Oxford

DaltonTx, a UK-based technology company, has completed a £4 million seed financing round to develop adaptive AI-enabled discovery platforms that reshape R&D economics and timelines.

Genentech has entered an exclusive collaboration with OMass Therapeutics to develop oral small molecules targeting a first-in-class inflammatory bowel disease target, with $20 million upfront and over $400 million in potential milestone payments.

OrganOx, the Oxford-based medtech company behind pioneering liver perfusion technology, has been acquired by Terumo Corporation for approximately $1.5 billion.

Circle Pharma's CID-078, a first-in-class oral cyclin A/B RxL inhibitor, demonstrated robust anti-tumor activity in preclinical models, including chemotherapy-resistant small cell lung cancer xenografts.

Upperton Pharma Solutions has secured funding from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for adenovirus-vectored vaccines in collaboration with the University of Oxford.

MIT researchers used generative AI to design two novel antibiotics capable of killing drug-resistant gonorrhea and MRSA in laboratory and animal tests.

Ultromics raised $55 million in Series C funding to expand its FDA-cleared EchoGo platform for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis across US hospitals.

The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya.

Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.

Two independent studies demonstrate that intranasal COVID-19 vaccination induces robust mucosal immunity, including durable IgA responses and tissue-resident memory T cells in the respiratory tract, which intramuscular vaccination fails to achieve.